NEW YORK, Feb. 11 - Morewood Molecular Sciences has licensed high-throughput technology from Harvard University that the company hopes will "leverage" its own technology for ultra-fast enzymatics.
The license, which covers a method of high-throughput screening of certain undisclosed molecules, may "enhances Morewood's foundation technology for some applications, for ultra high throughput assaying of enzyme activity, and for point-of-care diagnostics," the company said on Monday. In return, Harvard agreed to acquire an equity interest in the firm.
Financial details of the non-exclusive agreement were not disclosed.
Morewood, a spin-off of Pittsburgh-based LaunchCyte, is a private company that develops technologies for assaying enzyme activities, including in-vitro diagnostics. It also provides ultra high-throughput screening of drug candidates. Morewood has offices in Pittsburgh and Philadelphia.